The Leukaemia Foundation provided consumer comments to the Pharmaceutical Benefits Advisory Committee (PBAC) in relation to Otsuka Australia Pharmaceutical’s resubmission for decitabine and cedazuridine (Inqovi®) for high-risk MDS and CMML.
Julian Lindsay’s goal is to set up an international study aimed at improving survival and quality of life through drug optimisation.
Associate Professor Michael Dickinson says CAR T-cell therapy is a 'revolutionary step forward'.
These two myeloma drugs were not recommended for listing on the PBS.
Two clinical trials will open later this year for newly diagnosed patients with AL amyloidosis with moderate to severe cardiac disease.
The drug has received a positive recommendation for PBS listing.
Shirley Irwin has had radiotherapy and two transplants, had surgery, five different lines of treatment, and relapsed twice.
Jack was 22 years old when he was diagnosed with a dangerous blood disorder called aplastic anaemia.
Dr Bruce Levine explains how it works and why.
